Hologic Inc's Cash & cash equivalent grew by 7.35 % in the Q1 2025 sequentially, while Current Liabilities decreased, this led to improvement in Hologic Inc's Quick Ratio to 2.49, above Hologic Inc average Quick Ratio.

Within Medical Laboratories industry Hologic Inc booked the highest Quick Ratio than Hologic Inc in the first quarter 2025. While Quick Ratio total ranking has improved so far during the Q1 2025 to 170, from total ranking in the fourth quarter 2025 at 762.

Explain Quick Ratio?
How much Cash & cash equivalents HOLX�s has?
What are HOLX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

HOLX Quick Ratio	(Dec 27 2025) Q1	(Sep 27 2025) Q4	(Jun 28 2025) Q3	(Mar 29 2025) Q2	(Dec 28 2024) Q1
Y / Y Current Liabilities Change	-5.13 %	-5.82 %	105.07 %	115.8 %	137.37 %
Y / Y Cash & cash equivalent Change	19.87 %	-5.61 %	-22.96 %	-	2.1 %
Quick Ratio MRQ	2.49	2.26	1.96	1.64	1.97
HOLX's Total Ranking	# 170	# 762	# 610	# 972	# 727
Seq. Current Liabilities Change	-2.66 %	1.52 %	-2.77 %	-1.27 %	-3.37 %
Seq. Cash & cash equivalent Change	7.35 %	17.22 %	15.92 %	-17.83 %	-15.47 %

Quick Ratio first quarter 2025 Company Ranking
Within:	No.
Medical Laboratories Industry	# 1
Healthcare Sector	# 44
Overall Market	# 170

Quick Ratio Statistics
High	Average	Low
2.5	1.02	0.29
(Sep 24 2022)		(Dec 29 2018)

Financial Statements
Hologic Inc's Current Liabilities	$ 948 Millions	Visit HOLX's Balance sheet
Hologic Inc's Cash & cash equivalent	$ 2,365 Millions	Visit HOLX's Balance sheet
Source of HOLX's Sales		Visit HOLX's Sales by Geography

Cumulative Hologic Inc's Quick Ratio

HOLX's Quick Ratio for the trailling 12 Months

HOLX Quick Ratio	(Dec 27 2025) 12 Months	(Sep 27 2025) 12 Months	(Jun 28 2025) 12 Months	(Mar 29 2025) 12 Months	(Dec 28 2024) 12 Months
Y / Y Current Liabilities TTM Growth	30.74 %	64.66 %	74.49 %	53.94 %	30.89 %
Y / Y Cash & cash equivalent TTM Growth	19.6 %	14.48 %	10.05 %	79.74 %	44.92 %
Quick Ratio TTM	2.09	1.96	1.96	2.4	2.28
Total Ranking TTM	# 978	# 2422	# 1145	# 2481	# 691
Seq. Current Liabilities TTM Growth	-1.31 %	-1.51 %	14.09 %	17.9 %	24.3 %
Seq. Cash & cash equivalent TTM Growth	5.11 %	-1.68 %	-6.69 %	24.03 %	0.61 %

Quick ratio ranking by company, industry and sector >> Back to HOLX Financial Strength Comparisons >> Go to Compare HOLX Quick Ratio to its Competitors

On the trailing twelve months basis HOLX Cash & cash equivalent increased by 19.87 % in Q1 2025 year on year, while Current Liabilities decreased to $948 millions, this led to increase in in Hologic Inc's Quick Ratio to 2.09, above HOLX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 7 other companies have achieved higher Quick Ratio than Hologic Inc. While Quick Ratio overall ranking has improved so far to 978, from total ranking during the twelve months ending fourth quarter 2025 at 2422.

Explain Quick Ratio?
How much Cash & cash equivalents HOLX�s has?
What are HOLX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Laboratories Industry	# 8
Healthcare Sector	# 140
Within the Market	# 978

trailing twelve months Quick Ratio Statistics
High	Average	Low
2.08	0.83	0.34
(Dec 27 2025)		(Dec 28 2019)

Companies with similar Quick Ratio in the quarter ending Dec 27 2025, within Medical Laboratories Industry	Quick Ratio	Dec 27 2025 MRQ Cash & cash equivalent	Dec 27 2025 MRQ Current Liabilities
Veracyte Inc	6.63	$ 362.578 Millions	$ 54.726 Millions
Personalis Inc	6.05	$ 239.953 Millions	$ 39.630 Millions
Omniab Inc	5.86	$ 54.025 Millions	$ 9.214 Millions
Castle Biosciences Inc	4.36	$ 299.505 Millions	$ 68.677 Millions
Guardant Health Inc	3.97	$ 1,201.598 Millions	$ 302.730 Millions
Fulgent Genetics Inc	3.96	$ 336.077 Millions	$ 84.967 Millions
Nano X Imaging Ltd	3.28	$ 59.610 Millions	$ 18.148 Millions
Grail Inc	3.13	$ 249.727 Millions	$ 79.670 Millions
Hologic Inc	2.49	$ 2,364.700 Millions	$ 947.800 Millions
Exagen Inc	2.28	$ 32.220 Millions	$ 14.159 Millions
Caredx Inc	2.24	$ 201.329 Millions	$ 89.849 Millions
Butterfly Network Inc	2.23	$ 150.489 Millions	$ 67.595 Millions
Bioaffinity Technologies Inc	2.22	$ 6.450 Millions	$ 2.906 Millions
Incyte Corporation	2.04	$ 3,097.817 Millions	$ 1,519.925 Millions
Burning Rock Biotech Limited	1.95	$ 68.752 Millions	$ 35.179 Millions
Sera Prognostics Inc	1.62	$ 39.201 Millions	$ 24.188 Millions
Exact Sciences Corporation	1.59	$ 964.711 Millions	$ 607.561 Millions
Radnet Inc	1.38	$ 807.504 Millions	$ 586.763 Millions
Ispecimen inc	1.11	$ 6.893 Millions	$ 6.231 Millions
Biodesix Inc	1.09	$ 18.987 Millions	$ 17.436 Millions
Medpace Holdings Inc	1.02	$ 497.049 Millions	$ 489.358 Millions
Advanced Biomed Inc.	0.95	$ 2.608 Millions	$ 2.747 Millions
Lumexa Imaging Holdings Inc	0.60	$ 58.828 Millions	$ 98.015 Millions

Date modified: 2026-09-26T06:54:28+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.